Physician profile
Sabin Tomus
NPI 1689616963
$4,036.25
in general payments reported to CMS, 2019-2025
32 companies · $624 in 2025
The $624 reported for 2025 was more than what 77% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $235 · 2020: $434 · 2021: $716 · 2022: $565 · 2023: $662 · 2024: $801 · 2025: $624.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,086.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,086.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $931.30 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $640.06 | 2020-2025 | Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $337.83 | 2022-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals LP | $313.73 | 2020-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $257.06 | 2019-2025 | |
| Abbvie INC. | $196.46 | 2020-2025 | Ubrelvy |
| Amgen INC. | $191.38 | 2020-2023 | Otezla, Repatha |
| Idorsia Pharmaceuticals US INC | $139.88 | 2022-2023 | Quviviq |
| Astellas Pharma US INC | $125.80 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $83.87 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $82.98 | 2021-2024 | Glassia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $82.88 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $80.18 | 2020-2024 | Spravato |
| Dexcom, INC. | $77.67 | 2022-2025 | Dexcom G6 Transmitter |
| Xeris Pharmaceuticals, INC. | $70.87 | 2021-2025 | Gvoke Hypopen |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $60.05 | 2024-2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $52.58 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $36.38 | 2020-2021 | |
| Eisai INC. | $31.12 | 2021-2022 | |
| Axsome Therapeutics, INC. | $29.26 | 2023 | Sunosi |
| Allergan, INC. | $25.23 | 2020 | |
| Ardelyx, INC. | $23.56 | 2024 | Ibsrela |
| Abbott Laboratories | $21.37 | 2021 | |
| Ars Pharmaceuticals Operations, INC. | $21.34 | 2025 | Neffy |
| Biohaven Pharmaceutical Holding Company LTD. | $20.46 | 2022 | |
| Esperion Therapeutics, INC. | $16.63 | 2022 | |
| Sunovion Pharmaceuticals INC. | $16.24 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $16.12 | 2024 | Caplyta |
| Amarin Pharma, INC. | $15.01 | 2020 | |
| Hikma Pharmaceuticals USA | $14.28 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $13.83 | 2021 | |
| Arbor Pharmaceuticals, INC. | $10.84 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sabin Tomus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.